Journal Club: All Recent News

Novartis Says Court Battle Will Delay Its Enbrel Copy Until 2018 at Least

(Jan 25 2017)

Spotlight On: Will sourcing acceptable reference products make US biosimilar interchangeability studies cost-prohibitive?

(Jan 24 2017)

Ewopharma Partners with Biogen to Commercialise BENEPALI and FLIXABI in Central Eastern Europe

(Jan 23 2017)

European Commission Initiative Improves Information for Patients on Biosimilar Medicines

(Jan 23 2017)

Celltrion to Expand Presence in US With FDA's New Guidance

(Jan 19 2017)

Physician Views Poll Results: Naming convention for biosimilars could be largely 'meaningless' after all – physicians indicate marginal impact on future adoption trends

(Jan 18 2017)

Biosimilars Create Opportunities for Sustainable Cancer Care

(Jan 18 2017)

Boehringer Ingelheim biosimilar candidate to Humira accepted for EMA and FDA regulatory review

(Jan 18 2017)

Physician Views: Benchmarking oncologist comfort levels with Celltrion's biosimilar MabThera

(Jan 18 2017)

From our perspective: Interchangeable biological products

(Jan 17 2017)

Physician Views: Will new FDA naming conventions for biosimilar products support or deter future uptake…?

(Jan 16 2017)

ASBM Statement on Final Guidance for Industry Nonproprietary Naming of Biological Products

(Jan 15 2017)

US Supreme Court agrees to hear Novartis' challenge of rule governing biosimilar launches

(Jan 13 2017)

Nonproprietary Naming of Biological Products - Guidance for Industry

(Jan 13 2017)

U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Trastuzumab

(Jan 11 2017)

JP Morgan 2017: Novartis CEO highlights subtle shift in biosimilar pricing environment

(Jan 10 2017)

Coherus BioSciences Announces Positive Topline 24-Week Treatment Phase Three Results for CHS-1420 (HUMIRA Biosimilar Candidate) in Patients with Psoriasis

(Jan 10 2017)

Pfizer Announces Positive Top-Line Results from the Comparative REFLECTIONS B538-02 Study for PF-06410293, a Potential Biosimilar to Humira1 (adalimumab)

(Jan 5 2017)

Biologics enter top selling drugs’ list

(Dec 28 2016)

Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon's Proposed Biosimilar Trastuzumab Phase 3 Data

(Dec 27 2016)

Pages